





## TEOXANE LABORATORIES ARE LAUNCHING AN EXCLUSIVE NEW FORMULATION OF TEOSYAL® KISS

**TEOSYAL®** Kiss New Formulation is a hyaluronic acid-based filler specifically adapted to the mobility of the lips. It offers a long-lasting efficacy thanks to its high cohesivity. With this innovative formulation, **TEOXANE Laboratories offer enhanced safety, tolerability and natural results** for this delicate area. Owing to its **ideal elastic profile**, this **smooth gel** is very **soft** and **easy to inject**, allowing optimal control of the injection for the practitioner.

The perioral area is the **second esthetic concern of women** after the eye area<sup>1</sup>. This delicate area is very sensitive and highly vascularized, therefore a specifically adapted product is a must to obtain optimal results. **TEOSYAL® Kiss New Formulation redefines** the lips' contour and corners, **enhances** the lips' texture with more hydration and softness and **plumps** the lips in harmony for a well-balanced correction.

**TEOSYAL®** Kiss New Formulation is also available with lidocaine (0,3%) for more comfort for the patient. Thanks to harmonious and natural results, TEOSYAL® Kiss proved its efficacy and is the perfect answer to patients' needs as **94%** would recommend a treatment with Kiss New Formulation, and **82%** would do it again<sup>2</sup>.





## **About TEOXANE Laboratories**

TEOXANE Laboratories were established in Geneva in 2003 and are specialized in the design and manufacture of hyaluronic acid-based dermal fillers. As a result of its uncompromising commitment to innovation, quality and patient satisfaction, TEOXANE is now among the top three hyaluronic acid-based dermal fillers manufacturers in the world with products in more than 80 countries. For more information, please visit www.teoxane.com.

## PRESS CONTACT

Pauline Béroard, Communication Officer E-mail: p.beroard@teoxane.com Phone: +33 1 44 40 88 90

<sup>&</sup>lt;sup>2</sup> Post-market clinical investigation on Teosyal® Kiss New Formulation made in October 2012 on 26 patients (women only, average age 41 years old) followed by 13 practitioners.



Arcane research study done in France in February 2011 on 4 402 women aged between 18 and 75 years old.